Combining limited evidence on chikungunya: a systematic literature review and meta-analysis on clinical outcomes

Authors: Timon Louwsma1,2, Giorgia Tiozzo1,2, Kris Rama2, Gerard T Vondeling3, Adrianne de Roo3

Affiliation(s): 1 Department of Health Sciences, University Medical Center Groningen, Groningen, Netherlands; 2 Asc Academics B.V. Groningen, Netherlands; 3 Valneva, Market Access & Value Evidence, Vienna, Austria

Introduction

Disease background

• Chikungunya is a viral disease caused by a mosquito-borne alphavirus, the chikungunya virus (CHIKV).
• The virus is characterized by an acute phase (commonly presenting with fever, arthralgia, and myalgia), with a variable proportion of individuals (30%-40%) also developing chronic symptoms that can be present for months or even years (including chronic arthralgia, fatigue, stiffness, and depression among others).1,2
• Due to global warming and mosquito vector spread, the disease has rapidly expanded, and currently over three-quarters of the world’s population lives in the areas at risk of CHIKV transmission.2

Problem statement

• The increased frequency of chikungunya outbreaks in recent decades, along with the ongoing spread of the virus, has led to a substantial adverse impact on societies and healthcare systems. Despite these challenges and the high mortality rates associated with chikungunya, specific treatments or preventive vaccines for the disease are currently unavailable, and the evidence is limited.

Objective:

• The objective aimed to improve the current evidence on chikungunya by combining clinical data on the disease through a meta-analysis.

Methods

Clinical systematic literature review (cSLR)

• The process to identify sources that could be used in meta-analysis consisted of two stages: initial and updated cSLR.
• The cSLR data search was performed following the requirements of global health technology assessment (HTA) agencies, with the searches conducted in MEDLINE In-Process, Embase and MEDLINE.
• Strict PICOS criteria were created to ensure only relevant articles would be identified through the cSLR.
• The cSLR identified relevant articles for meta-analysis, extracting key information on study design, patient characteristics, and clinical presentation into a standardised data extraction table shell in Microsoft Excel.

Feasibility assessment and meta-analysis

• A feasibility assessment was carried out to ensure the comparability of selected studies for meta-analysis.
• We conducted a manual assessment to check the comparability of the populations in any identified outlier group.
• Meta-analyses were performed for various endpoints related to the frequently reported clinical symptoms of chikungunya, including mortality rates, incidence of symptoms, and frequency of hospitalization.
• The results of each meta-analysis were presented using a forest plot, which displayed the effect size for each study along with the numerical and graphical representation of the confidence interval.

Results

A total of 316 articles were included in the cSLR and considered in the meta-analysis.

Acute hospitalization

• On average, 17% of symptomatic adults with confirmed chikungunya are hospitalized during the acute phase.

Mortality

• In populations with a normal mortality risk, the estimated death rate from CHIKV infection is 0.32%.
• In high-risk populations, the estimated death rate from CHIKV infection is 15% (Figure 1).

Chikungunya symptoms

• It is estimated that 73.8% of individuals infected with CHIKV experience a symptomatic disease.
• Arthralgia and fever are the most frequently reported symptoms of chikungunya.
• On average, 43.4% of patients with acute chikungunya transition to chronic disease, and about 50% of these chronic patients do not recover from the disease.
• The chronicity rate is projected at 43.8% after three months, declining to 34.9% after six months, and further decreasing to 31.87% after 12 months.

Endpoints without data availability

• The meta-analysis estimation of several endpoints proved to be infeasible due to their infrequent reporting in the studies identified through the cSLR. Among others, these endpoints include the duration of each symptom, length of acute and chronic illness, and hospitalization of chronic patients.

Discussion

• Chikungunya is associated with a significant disease burden: 73.8% of infected individuals experience symptomatic disease, with arthralgia, fever, and joint pain constituting the most frequently reported symptoms of CHIKV infection.
• Patients 65 years or older presented a relatively higher mortality rate, increased hospitalisation rates, and a lower incidence of symptoms compared to other age groups. To gain a deeper understanding of the potential influence of this demographic, future analysis could try to assess the overall impact of age on disease outcomes in CHIKV infection.
• This study included all reported subgroups rather than just the studies themselves. This approach provided the advantage of including more populations reporting the desired endpoint, resulting in a sufficient number of groups for meta-analysis and better control of heterogeneity.
• A limitation of this study was the presence of heterogeneity among studies. This can be explained by the collection of data on chikungunya, which is predominantly conducted during outbreaks, limiting the ability to establish strict scientific protocols and control various parameters, and by lack of consensus regarding the standardized reporting of endpoints.
• The field of chikungunya is characterized by novelty and uncertainty, reflected by the unexpectedly low number of 15 meta-analyses that could be conducted out of the 33 endpoints of interest. Therefore, more structured research is essential to understand chikungunya comprehensively.

Acknowledgements

The authors would like to acknowledge Yelena Hidatsa, Gabriel Gargul and Fiona Kestler for the contribution to the execution of the study.

References


Disclosures

This project was funded by Valneva SE. Timon Louwsma, Giorgia Tiozzo, and Kris Rama are employees of Asc Academics. Asc Academics has received consultancy fees for this project from Valneva SE. G. Vondeling and A de Roo are paid employees at Valneva SE.

Contact the author at: Timon.Louwsma@ascacademics.com

ISPOR Europe 2023, 12 – 15 November